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Abstract: Monogenic hypertension is rare and caused by genetic mutations, but whether factors
associated with mutations are disease-specific remains uncertain. Given two factors associated with
high mutation rates, we tested how many previously known genes match with (i) proximity to
telomeres or (ii) high adenine and thymine content in cardiovascular diseases (CVDs) related to
vascular stiffening. We extracted genomic information using a genome data viewer. In human chro-
mosomes, 64 of 79 genetic loci involving >25 rare mutations and single nucleotide polymorphisms
satisfied (i) or (ii), resulting in an 81% matching rate. However, this high matching rate was no longer
observed as we checked the two factors in genes associated with essential hypertension (EH), thoracic
aortic aneurysm (TAA), and congenital heart disease (CHD), resulting in matching rates of 53%,
70%, and 75%, respectively. A matching of telomere proximity or high adenine and thymine content
projects the list of loci involving rare mutations of monogenic hypertension better than those of other
CVDs, likely due to adoption of rigorous criteria for true-positive signals. Our data suggest that the
factor–disease matching rate is an accurate tool that can explain deleterious mutations of monogenic
hypertension at a >80% match—unlike the relatively lower matching rates found in human genes of
EH, TAA, CHD, and familial Parkinson’s disease.
Keywords: hypertension; congenital heart disease; thoracic aortic aneurysm; telomere; adenine
thymine content; single nucleotide polymorphism (SNP); Parkinson’s disease
1. Introduction
Hypertension remains the single biggest risk factor contributing to the global burden
of disease and mortality [1]. Despite the prevalence of individuals with elevated blood pres-
sure, the role of genetics in hypertension is poorly understood. Butler cited that 30%–50% of
the variance of blood pressure readings is attributable to genetic heritability and about 50%
is attributable to environmental factors [2]. With the advent of new molecular techniques,
genetic mutations linked to monogenic hypertension (MH) have been found, suggesting
that understanding the pathologies of these monogenic disorders provides insight into
the causes of the more prevalent essential hypertension (EH) and new avenues to unravel
the complexities of blood pressure regulation [3]. We have recently demonstrated that
mutations causative of the congenital disorder can be projected by a stochastic approach
centered on chromosomal characteristics of human genomes [4]. Germline mutations,
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which are created by homologous recombination, are estimated to occur in humans with
an average probability of 1.28 × 10−8 per site per generation, with ∼93% of these be-
ing point mutations [5,6]. Germline point mutations can result in the creation of single
nucleotide polymorphisms (SNPs) in a population [7]. Mutations have been proposed
as natural variations that contribute to both intraspecies diversity (human genome) and
interspecies divergence [8–11]. Several factors associated with these mutations have been
implicated, including whether they are advantageous, neutral, or deleterious in human
genomes and/or between species [8,9,12]. Excluding the impact of the father’s age at
conception [13], there is an estimated 63–65 mutations per generation in humans, with 1–2
of these being considered deleterious.
Genes that satisfy one or more of these criteria are more likely to undergo mutations
in the next generation. However, whether these mutations are advantageous, neutral,
and/or deleterious is not determinable until the phenotype has been confirmed. Genes
can be categorized as being causative of the disease or associated with the disease. Genes
are considered causative if they can be directly linked to the expected phenotype, often
determined in model systems with a phenotype that is comparable to that seen in humans.
On the other hand, associated genes are those in which the cause and effect of the gene
and its phenotype cannot be explained by genetic factors alone. Genes associated with
essential hypertension (EH) and Alzheimer’s disease [4] are valid examples of how genetic
and environmental factors may both contribute to the disease phenotype. In this study, we
also use the term ‘genetic susceptibility’ when we refer to a candidate gene susceptible to
the disease with an additional contributor [14].
Arterial stiffening, an independent predictor of cardiovascular morbidity and mor-
tality, plays an important role in cardiovascular diseases (CVDs) [15,16], including hy-
pertension [17,18], congenital heart disease (CHD) [19], and thoracic aortic aneurysms
(TAA) [20,21]. Given the multigenic causes of these conditions, elucidation of the genetic
characteristics or factors impacting high mutation rates might reduce the burden of high
mortalities [22] in these CVDs. Furthermore, understanding the inherited genomic charac-
teristics associated with arterial stiffening might lead to improved diagnosis and treatment
of hypertension, CHD, and TAA. This idea, along with increasing evidence from human
genome sequencing, suggests that select CVDs such as hypertension, CHD, and TAA most
likely result from the interaction of various genetic and environmental cues [23–29].
Several factors have been reported to be associated with high mutation rates, including
recombination rate, proximity to a telomere (F(i)) [30], and high A+T content (F(ii)) [9,12,31].
Among these factors, we have previously shown that F(i) [8] and F(ii) can explain some of
the genetic mutations linked to monogenic and/or degenerative disorders [4]. However,
whether these factors can provide a quantitative clue by percent on the genetic and/or
environmental contributions to CVDs remains unclear.
Telomeres—which are essentially characterized by a unique chromatin environment [30]—
are composed of 3–20 kb of A+T rich repeats flanked by subtelomeric regions extending
up to 300 kb into the chromosome [32]. Furthermore, tandem repeats of short GT-rich
sequences are characteristic of almost all eukaryotic telomeres [33]. Specifically, human
telomeres range in size from 2 to 50 kb and consist of 300–8000 precise repeats of the
sequence CCCTAA/TTAGGG. A common feature of all telomeres is the orientation of the
G-rich strand. In all cases, this strand comprises the 3′-end of the chromosome, while its
terminal part is single-stranded, generating a G-tail [34].
Here, we investigate the two aforementioned chromosomal factors to determine
whether they are associated with high mutation rates in human genes related to CVDs.
By analyzing the sets of genes published previously for hypertension, CHD, and TAA,
we aim to determine how many genes satisfy the two factors F(i) and F(ii) [4,12]. To do
so, we compare the matching rate of these two criteria to the disease, focusing on the
gene transcripts and/or genes near the loci involving coding and non-coding regions
obtained from four independent prior studies. We provide the factor–disease matching
rate of EH, which a majority of individuals with hypertension have. Then, we assess how
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many genes near the loci involving >25 rare mutations and 53 SNPs contributing to the
genetic architecture of hypertension meet F(i) or F(ii), leading to an alternative conclusion.
Subsequently, we demonstrate whether mutations causing CHD would satisfy either F(i)
or F(ii). To this end, we show how genes associated with TAA reveal the factor–disease
matching rate and provide a comprehensive summary of genomic features associated with
mutations in CVDs as compared to those of neurological disorders.
2. Results
2.1. Forty-One Genes Associated with Idiopathic or Essential Hypertension (EH)
In assessing the list of the proposed genes of EH in Table S1, we surveyed the distance
between each gene locus and its telomere using the F(i). As we identified 41 gene loci
listed in Table S1, the candidate genes of EH are mostly skewed towards chromosome one
(Figure 1A,B).




Figure 1. Genes associated with essential hypertension (EH) from microsatellite analysis. (A) A cartoon illustrating a dis-
tance to a telomere (arrows) from a gene in a human chromosome [12]. (B) Box and violin plots showing the distribution 
of 41 genes associated with EH with respect to proximity to telomeres over chr 1 to 11. F(i) indicates the first factor, namely 
proximity to the telomere. (C) Box and violin plots summarizing the full distribution of genes associated with EH with 
respect to A+T content over chr 1, 5, and 11. F(ii) indicates the second factor, namely high A+T content at >59%. (D) Bar 
graph demonstrating factors–EH matching rate. (E) Scatter plot exhibiting the Pearson correlation between the full length 
(base or b) of genes associated with EH and their proximity to telomeres. (E’) Scatter plot showing the Pearson correlation 
between the full length of genes associated with EH and A+T content. (F) Scatter plot showing proximity to telomeres of 
genes associated with EH with respect to three subgroups of the gene full-length size. A horizontal dotted line indicates 
50 Mb. (G) Scatter plot summarizing A+T content of genes associated with EH with respect to the gene size in base or b. 
A horizontal dotted line indicates 59%. The statistical difference after one-way ANOVA among three groups of 1 to 3000, 
3001 to 6000, and 6001 to 17,000 at p > 0.05 (F,G). 
2.2. Rare Mutations and SNPs Contributing to the Genetic Architecture of Hypertension 
With a myriad of intriguing mismatches between the two considered factors and EH 
obtained through microsatellite markers, we asked what differed in the EH study of Fig-
ure 1 as compared to the previous investigations on CNS disorders [4]. Using the refined 
literature search mentioned in the methods section, we investigated the position of 79 
genes near the loci proposed for hypertension (Table S2). In assessing the list of genes 
susceptible to hypertension in Table S2, we found that the list of >25 rare mutations (mon-
ogenic) and 53 SNPs were distributed over almost all chromosomes (Figure 2A). Our ob-
servation of the human chromosomes confirmed that susceptible genes located in chr 18, 
19, and 20 were more prone to mutations because they more likely satisfied F(i) than genes 

















































































































































































































































































































































































































































Fi re 1. Genes associated with essential hypertension (EH) fro microsatellite analysis. (A) A cartoon illustrating a
distance to a telomere (arrows) from a g ne in a human chromosome [12]. (B) Box and violin plots showing the distribution
of 41 genes associate it E ith respect to proxi it to telo er s er c r 1 to 11. F(i) indicates the first factor, na ely
proxi ity to the telo ere. (C) Box and violin plots su arizing the full distribution of genes associated ith E ith
respect to A+T content over chr 1, 5, and 11. F(ii) indicates the second factor, namely high A+T content at >59%. (D) Bar
graph demonstrating factors–EH matching rate. (E) Scatter plot exhibiting the Pearson correlation between the full length
(base or b) of genes associated with EH and their proximity to telomeres. (E’) Scatter plot showing the Pearson correlation
between the full length of genes associated with EH and A+T content. (F) Scatter plot showing proximity to telomeres of
genes associated with EH with respect to three subgroups of the gene full-length size. A horizontal dotted line indicates
50 Mb. (G) Scatter plot summarizing A+T content of genes associated with EH with respect to the gene size in base or b. A
horiz ntal dotte line indicates 59%. The statistical difference after one-way ANOVA among three groups of 1 to 3000, 3001
to 6000, and 6001 to 17,000 at p > 0.05 (F,G).
To further assess this notion, we obtained the A+T content of genes associated with
EH. Genes associated with EH rarely met high A+T content at >59% (Figure 1C). As we
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identified the relationship between the two aforementioned factors and the disease, ~53%
of genes satisfied the proximity to telomeres or high A+T content (n = 22/41). Intriguingly,
almost half of the genes (18 of 41) associated with EH met neither F(i) nor F(ii). Furthermore,
only 2 of 41 genes met both F(i) and F(ii) (Figure 1D).
During analysis of the DNA composition of each gene, we asked if the full-length
size of a gene, if it was larger than 6000 bp, was related to A+T content. The Pearson
coefficient (r = 0.07) indicated that there was no significant correlation (p = 0.67) between
the full-length sizes of the genes and proximity to telomeres in EH. We found no significant
correlation between the full-length size and A+T content (r = −0.2; p = 0.19) (Figure 1E,E’).
We then evaluated factors (i) and (ii) with respect to the base pair of each gene
associated with EH. We grouped these forty-one genes into three categories: 1–3000 bp
(n = 16), 3001–6000 bp (n = 15), and 6001–17,000 bp (n = 10) (Table S1). Statistical analysis
suggested that there was no significant difference in proximity to telomeres with respect to
the gene full-length size (p > 0.3). Furthermore, pairwise comparisons using Tukey’s post
hoc test after one-way ANOVA suggested that there was no significant difference (p > 0.5)
in A+T content with respect to the full-length size (bp) between the groups (Figure 1F,G).
Overall, the mismatch of two factors and the disease (EH) as well as the correlation
between the full-length size of the genes and A+T content was either unexpectedly low
(~53%) or statistically insignificant.
2.2. Rare Mutations and SNPs Contributing to the Genetic Architecture of Hypertension
With a myriad of intriguing mismatches between the two considered factors and
EH obtained through microsatellite markers, we asked what differed in the EH study
of Figure 1 as compared to the previous investigations on CNS disorders [4]. Using the
refined literature search mentioned in the methods section, we investigated the position
of 79 genes near the loci proposed for hypertension (Table S2). In assessing the list of
genes susceptible to hypertension in Table S2, we found that the list of >25 rare mutations
(monogenic) and 53 SNPs were distributed over almost all chromosomes (Figure 2A). Our
observation of the human chromosomes confirmed that susceptible genes located in chr 18,
19, and 20 were more prone to mutations because they more likely satisfied F(i) than genes
in other chromosomes.
To further test our hypothesis regarding F(ii), we obtained the A+T content of genes
near the loci proposed for hypertension. When we examined 79 genes susceptible to MH
and contributing to the genetic architecture of hypertension focusing on the factor–disease
matching rate, >81% exclusively satisfied either the F(i) or F(ii) (n = 64/79) condition.
Unlike the previous study (Figure 1C), a quarter of these genes displayed high A+T
content at higher than 59% (Figure 2B). Sixteen percent of genes (13 of 79) associated with
hypertension met neither F(i) nor F(ii). Furthermore, 2 of 79 genes met both F(i) and F(ii)
(Figure 2C). This lends stronger support to the idea that if there is a match between the
factor and the disease, telomere proximity or A+T content will suffice to explain deleterious
mutations and SNPs in both coding region and non-coding RNA (>81% match) (Figure 2C).
The Pearson coefficient of r = 0.02 suggested that there was no significant correlation
(p = 0.88) between the full-length size and the F(i) in hypertension (Figure 2D). However,
the Pearson coefficient between the full-length size and F(ii) (r = 0.53) suggested that there
was a significant correlation (p < 0.0001) (Figure 2D’; highlighted in color).
We then organized genes according to two factors with respect to the base pair
length. Consistent with the previous analysis [4], we grouped genes into three categories:
1–3000 bp (n = 22), 3001–6000 bp (n = 29), and 6001– 17,000 bp (n = 28). We found that
there was no significant correlation between the F(i) and the full-length size of the gene
(p > 0.05) (Figure 2E). However, the pairwise comparisons suggested that there was a sig-
nificant correlation (p < 0.0001) between F(ii) and the full-length size (bp) when comparing
three groups sorted by the nucleotide size (Figure 2F).




Figure 2. Genes (n = 79) near the loci susceptible to MH from exome sequencing and GWAS/SNPs analysis. (A) Box and 
violin plots showing the distribution of 79 genes near the loci proposed as candidates for hypertension [35] with respect 
to proximity to telomeres over chr 1 to X. The candidate genes are widely distributed over almost all chromosomes. F(i) 
indicates the proximity to the telomere. (B) Box and violin plots summarizing the full distribution of genes susceptible to 
hypertension with respect to A+T content. F(ii) indicates high A+T content at >59%. (C) Bar graph demonstrating factors–
hypertension matching rate. (D) Scatter plot exhibiting the Pearson correlation between the full length of genes susceptible 
to hypertension and their proximity to telomeres. (D’) Scatter plot showing the Pearson correlation between the full length 
of genes susceptible to hypertension and A+T content. Pearson correlation at r = 0.53 with the level of statistical significance 
at p < 0.0001. (E) Scatter plot showing proximity to telomeres of 79 genes susceptible to hypertension with respect to three 
subgroups of the gene full-length size (unit: base or b). A horizontal dotted line indicates 50 Mb. (F) Scatter plot summa-
rizing A+T content of genes susceptible to hypertension with respect to the gene size in base or b. A horizontal dotted line 
indicates 59%. The statistical difference after one-way ANOVA among three groups of 1 to 3000, 3001 to 6000, and 6001 to 
17,000 at p < 0.05. * p < 0.05, ** p < 0.01, *** p < 0.005. 
To further test our hypothesis regarding F(ii), we obtained the A+T content of genes 
near the loci proposed for hypertension. When we examined 79 genes susceptible to MH 
and contributing to the genetic architecture of hypertension focusing on the factor–disease 
matching rate, >81% exclusively satisfied either the F(i) or F(ii) (n = 64/79) condition. Un-
like the previous study (Figure 1C), a quarter of these genes displayed high A+T content 
at higher than 59% (Figure 2B). Sixteen percent of genes (13 of 79) associated with hyper-
tension met neither F(i) nor F(ii). Furthermore, 2 of 79 genes met both F(i) and F(ii) (Figure 
2C). This lends stronger support to the idea that if there is a match between the factor and 
the disease, telomere proximity or A+T content will suffice to explain deleterious muta-
tions and SNPs in both coding region and non-coding RNA (>81% match) (Figure 2C).  
The Pearson coefficient of r = 0.02 suggested that there was no significant correlation 
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i li l ts i t e istri tion f es r t l i i tes f r rte si [ ] it t
t r i it t t l eres er c r t . t l i t i t r l st ll r s es. F(i)
i icates the proximity to the telomere. (B) Box and violin plots su marizing the full distribution of genes susceptible
to hypertension with respect to A+T content. F(ii) indicates high A+T content at >59%. (C) Bar graph demonstrating
factors–hypertension matching rate. (D) Scatter plot exhibiting the Pearson correlation between the full length of genes
susceptible to hypertension and their proximity to telomeres. (D’) Scatter plot showing the Pearson correlation between the
full length of genes susceptible to hypertension and A+T content. Pearson correlation at r = 0.53 with the level of statistical
significance at p < 0.0001. (E) Scatter plot showing proximity to telomeres of 79 genes susceptible to hypertension with
respect to three subgroups of the gene full-length size (unit: base or b). A horizontal dotted line indicates 50 Mb. (F) Scatter
plot summarizing A+T content of gen s susceptible to hypertension wit spect to the gene size in base or b. A horizon al
dotted line indicates 59%. The statistical difference after one-way ANOVA among three groups of 1 to 3000, 3001 to 6000,
and 6001 to 17,000 at p < 0.05. * p < 0.05, ** p < 0.01, *** p < 0.005.
2.3. Mapping of 57 Genes Causing CHD in Human Chromosomes
In our search of congenital cardiovascular defects, we found a recent report linking
cilia to heart defects, claiming that the likelihood of congenital heart disease (CHD) is up
to 10-fold higher in human fetuses, affecting nearly 1% of live births [36,37]. Thus, we
reviewed the relevant associated genes and summarized them (Table S3) [4]. Then, we
retrieved each transcript using the genome data viewer and checked the position of the p-
or q-arm of the chromosome relative to the telomere of 57 genes whose mutations causing
congenital heart disease (CHD) (Table S4).
In assessing the list of genes causative of CHD, we found that a substantial number
of listed genes were from mouse studies. After sorting out the duplicate genes appearing
multiple times (Tables S4 and S6) [37], we investigated 57 human genes (Table S4) and
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surveyed F(i) for each gene (Figure 3). As we identified 57 gene loci (Table S5), we again
observed that, in chromosomes of short physical length such as chromosome 19 and 22
(Figure 3A), causative genes were more likely to fulfill the F(i) as compared to those located
in other chromosomes.
To further test the hypothesis regarding F(ii), we obtained the A+T content of genes
whose mutations were reported to cause CHD. Although causal genes were widely dis-
tributed in almost all human chromosomes, a smaller number of genes met F(ii) (Figure 3B).
In assessing the factor–disease matching rate, >75% of genes causative of CHD satisfied the
F(i) (n = 39/57) or F(ii) (n = 11/57) conditions. Furthermore, 7 of 57 known genes met both
F(i) and F(ii), while ~25% (14 of 57 genes) belonged to neither F(i) nor F(ii) (Figure 3C). This
supported the idea that if there was a disease-specific matching of the previously proposed
two factors predicting genetic disorders of the heart, telomere proximity or A+T content
might be able to predict CHD at a >75% match.




Figure 3. Genes (n = 57) whose mutations cause CHD. (A) Box and violin plots showing the distribution of the genes over 
chromosomes (chr) 2 to 22 with respect to proximity to the telomere. (B) Box and violin plots showing the distribution of 
the genes over chr 2 to 22 with respect to A+T content. (C) Bar graph demonstrating factors–CHD matching rate. ‘F(i)or(ii)’ 
represents the genes causing CHD satisfying either proximity to the telomere within 50 Mb or A+T content higher than 
59%; ‘Both’ represents the genes meeting two factors alike. (D) Scatter plot showing the Pearson correlation between the 
full length of genes causing CHD and proximity to the telomere. (D’) Scatter plot demonstrating the Pearson correlation 
between the full length of genes causing CHD and A+T content. (E) Scatter plot showing 57 genes causing CHD with 
proximity to the telomere over full-length size of the gene. A horizontal dotted line indicates 50 Mb. (F) Scatter plot sum-
marizing 57 genes causing CHD with A+T content over full-length size of the gene (unit of base or b). A horizontal dotted 
line indicates A+T content at 59%. 
During the survey of nucleotide base pairs of the 57 genes, data entries suggested 
that the full-length size of a gene, if larger than 6000 bp, might indicate a high A+T content 
at >59%. Although a similar trend (upwards or increasing) was detected, the Pearson co-
efficient (r = 0.14) suggested that there was no significant correlation (p = 0.3) between the 
full-length size and F(i) in CHD. Intriguingly, the same was true for the relationship be-
tween the full-length size and F(ii) (r = 0.15; p = 0.25) (Figure 3D,D’). 
We then organized F(i) and F(ii) with respect to the base pair size of each gene. We 
grouped genes into three categories: 1–3000 bp (n = 14), 3001–6000 bp (n = 25), and 6001–
17,000 bp (n = 18) (Table S4; Figure 3E,F). There was no significant correlation in F(i) with 
respect to the gene full-length size (p = 0.3) (Figure 3E). Unlike the previous report [4], 
however, pairwise comparisons using Tukey’s post hoc test after one-way ANOVA sug-
gested that there was no significant correlation (p = 0.75) in F(ii) with respect to the full-
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between the full length of genes causing CHD and A+T content. (E) Scatter plot showing 57 genes causing CHD with
proximity to the telomere over full-length size of the gene. A horizontal dotted line indicates 50 Mb. (F) Scatter plot
summarizing 57 genes causing CHD with A+T content over full-length size of the gene (unit of base or b). A horizontal
dotted line indicates A+T content at 59%.
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During the survey of nucleotide base pairs of the 57 genes, data entries suggested that
the full-length size of a gene, if larger than 6000 bp, might indicate a high A+T content
at >59%. Although a similar trend (upwards or increasing) was detected, the Pearson
coefficient (r = 0.14) suggested that there was no significant correlation (p = 0.3) between
the full-length size and F(i) in CHD. Intriguingly, the same was true for the relationship
between the full-length size and F(ii) (r = 0.15; p = 0.25) (Figure 3D,D’).
We then organized F(i) and F(ii) with respect to the base pair size of each gene. We
grouped genes into three categories: 1–3000 bp (n = 14), 3001–6000 bp (n = 25), and
6001–17,000 bp (n = 18) (Table S4; Figure 3E,F). There was no significant correlation in
F(i) with respect to the gene full-length size (p = 0.3) (Figure 3E). Unlike the previous
report [4], however, pairwise comparisons using Tukey’s post hoc test after one-way
ANOVA suggested that there was no significant correlation (p = 0.75) in F(ii) with respect
to the full-length size (bp) between the groups (Figure 3F).
2.4. Mapping of 27 Genes Associated with TAA
Using a compilation of updated literature on TAA [38–40], we conducted our analysis
according to the literature selection criteria set forth previously in the methods [39]. We
checked the position of the p- or q-arm of the chromosome relative to the telomere of
27 genes associated with TAA (Table S5). In assessing the list of genes in Table S5, we
surveyed the distance between each gene locus and its telomere using the F(i) (Figure 4A).
As we identified 27 gene loci listed in Table S5, it was evident that, in chromosomes of short
physical length (e.g., chr 18–20), the “distance to a telomere” was within 50 Mb, thereby
fulfilling F(i).
To further test our hypothesis, we obtained the A+T content of genes associated with
TAA. Unlike CHD and other genetic disorders [4], genes associated with TAA rarely met
high A+T content at >59% (Figure 4B). When we examined two factors in 27 genes of
TAA, <66% satisfied the proximity to telomeres (n = 17/27) or high A+T content (n = 5/27)
conditions (collectively 70% for two factors). Evidently, 3 of 27 known genes met both F(i)
and F(ii), while ~28% (8 of 27 genes) belonged to neither F(i) nor F(ii). This suggests that
if there is a disease-specific matching of the previously proposed two factors, telomere
proximity or A+T content can explain TAA at 70% match (19 of 27) (Figure 4C).
During the survey of nucleotide base pairs of the 27 genes, data entries suggested that
the full-length size of a gene, if larger than 6,000 bp, might lead to the said gene having high
A+T content at >59%. Although a similar trend was found that was consistent with the
recent report [4], the Pearson coefficient (r = 0.16) suggested that there was no significant
correlation (p = 0.41) between the full-length size and proximity to telomeres in TAA. The
same was true for the relationship between the full-length size and A+T content (r = 0.12;
p = 0.54) (Figure 4D,D’).
We then organized F(i) and F(ii) with respect to the base pair of each gene. Consistent
with the previous analysis (Figures 1–3), we grouped genes into three categories: 1–3000 bp
(n = 6), 3001–6000 bp (n = 7), and 6001– 15,000 bp (n = 14) (Table S5). Statistical analysis
suggested that there was no significant difference in F(i) with respect to the gene full-length
size (p = 0.87). Furthermore, pairwise comparisons using Tukey’s post hoc test after one-
way ANOVA suggested that there was no significant difference (p = 0.5) in F(ii) with respect
to the full-length size (bp) between the groups (Figure 4E,F).




Figure 4. Genes (n = 27) associated with thoracic aortic aneurism (TAA) (A) Box and violin plots displaying the distribution 
of genes susceptible to TAA with respect to proximity to telomeres over chromosomes (chr) 1 to X. (B) Box and violin plots 
summarizing the full distribution of genes susceptible to TAA with respect to A+T content over chr 1 to X. (C) Bar graph 
demonstrating factors–TAA matching rate. (D) Scatter plot exhibiting the Pearson correlation between the full length of 
genes susceptible to TAA and their proximity to telomeres. (D’) Scatter plot showing the Pearson correlation between the 
full length (base or b) of genes associated with TAA and A+T content. (E) Scatter plot showing proximity to telomeres of 
27 genes susceptible to TAA with respect to three subgroups of the gene size by full length in base or b. A horizontal 
dotted line indicates 50 Mb. (F) Scatter plot summarizing A+T content of genes susceptible to TAA with respect to the gene 
size in base or b. A horizontal dotted line indicates 59%. The statistical difference after one-way ANOVA among three 
groups of 1 to 3000, 3001 to 6000, and 6001 to 15,000 at p > 0.05 (A, B, E, and F). 
3. Discussion 
Our review of idiopathic hypertension or EH [41] resulted in a challenging profile of 
hypertension candidate genes at the q-arm of chromosome 1. The idea that a poor match 
indicated that the disease (EH) was multigenic—while a higher match implied the disease 
was monogenic—needed to be further verified. Hence, we investigated the 79 loci associ-
ated with MH and contributing to the genetic architecture of hypertension [35], demon-
strating that genetic loci listed in this recent study [35] harbor a proximity to telomeres 
and nucleotide compositions (a ~81% match) similar to those 108 genes causative of con-
genital disease of the CNS. These two factors matched with the disease at ~90%, along 
with the significant correlation of the nucleotide size and A+T content (Table 1) [4]. Even 
as the literature [37] we sought for testing our hypothesis depicted a unique linkage from 
the causal genes to the congenital heart defect or CHD through cilia or ciliopathy-related 
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27 genes susceptible to TAA with respect to three subgroups of the gene size by full length in base or b. A horizontal dotted
line indicates 50 Mb. (F) Scatter plot summarizing A+T content of genes susceptible to TAA with respect to the gene size in
base or b. A horizontal dotted line indicates 59%. The statistical difference after one-way ANOVA among three groups of 1
to 3000, 3001 to 6000, and 6001 to 15,000 at p > 0.05 (A, B, E, and F).
3. Discussion
Our review of idiopathic hypertension or EH [41] resulted in a challenging profile
of hypertension candidate genes at the q-arm of chromosome 1. The idea that a poor
match indicated that the disease (EH) was multigenic—while a higher match implied
the disease was monogenic—needed to be further verified. Hence, we investigated the
79 loci associated with MH and contributing to the genetic architecture of hypertension [35],
demonstrating that genetic loci listed in this recent study [35] harbor a proximity to telom-
eres and nucleotide compositions (a ~81% match) similar to those 108 genes causative of
congenital disease of the CNS. These two factors matched with the disease at ~90%, along
with the significant correlation of the nucleotide size and A+T content (Table 1) [4]. Even
as the literature [37] we sought for testing our hypothesis depicted a unique linkage from
the causal genes to the congenital heart defect or CHD through cilia or ciliopathy-related
loci (Table S4) [4], the chromosomal characteristics of 57 genes causative of CHD (Figure 3)
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showed a similar feature (75% match) to genes proposed in MH (81% match) rather than
EH (53% match).
Table 1. Characteristics of genes associated with CVD and CNS disorders by two factors.
Cardiovascular System MH [35] CHD [37] TAA [39] EH [41]
Factor–disease match 81% 75% 70% 53%

























CNS CH [4] AD [4] fPD [4]
Factor–disease match >90% 84% 59%




















CVD: cardiovascular disease; CNS: central nervous system; MH: monogenic or Mendelian hypertension; CHD:
congenital heart disease; TAA: thoracic aortic aneurysm; EH: essential hypertension; Sig.: significant; NS: not
significant; FL: full-length (size of a gene); A+T: adenine and thymine content; CH: congenital hydrocephalus;
AD: Alzheimer’s disease; fPD: familial Parkinson’s disease.
A factor–disease matching rate higher than 80% indicates a likely correlation between
these factors and the mutations in a particular gene causative of the disease. In the case of
genetic hypertension or MH, 81% of examined genes satisfied either proximity to telomeres
or A+T content at >59%. This seems to indicate that the development of hypertension
can be directly influenced by mutations of these specific genes. Additionally, this high
factor–disease matching rate could provide a reliable method in the future of predicting
an individual’s risk of developing MH, at least for >25 rare mutations claimed by the
authors [35], through the examination of the family history and genetic mutations of
an individual.
On the other hand, if the factor–disease matching rate is closer to 50%—such as is
the case with EH—this seems to indicate a much more complex relationship between
the disease and its associated genes. Specifically, it is likely that this low matching rate
is indicative of the disease being multigenic in nature. Indeed, EH has been previously
identified as idiopathic in nature, meaning that a variety of factors impact its development.
While proximity to telomeres and A+T content can serve as an accurate predictive measure
for diseases that can be induced by a mutation in a single gene, it will inherently be much
less accurate at predicting diseases whose causes are not fully understood and documented.
Thus, this supports the idea that the factor–disease matching rate is much lower for this
idiopathic disease.
While the genes involved with MH, CHD, and TAA appear to be relatively long
in terms of base pair length, the genes involved with CH, AD, and fPD appear to be
much shorter in length. This significant difference in nucleotide length—yet relative
similarity as to factor–disease matching rates—potentially indicates the specific factor
evoking mutations (and therefore likely the type of mutation taking place) in each of these
genes. Since genes associated with diseases of the cardiovascular system are comparatively
longer compared to those associated with the CNS, it is potentially more likely that these
genes have a greater A+T content (>59%), on account of their greater nucleotide length. At
the same time, a longer gene is less likely to be located (at least entirely) within 50 Mb of the
telomere. While a shorter gene might easily fall within 50 Mb of the telomere, a much longer
gene might fall partially or entirely outside this proximity. This could result in a difference
of factor–disease matching rate—at least in terms of which factor(s) matched which disease—
between CVD and CNS disease. Based on the contents of Table 1, it is tempting to argue that
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the genes associated with the CNS—since they are both comparatively short in nucleotide
full length (FL) and have significant FL-A+T correlation—are more likely to meet both F(i)
and F(ii), while the genes associated with CVD potentially only meet one of the two factors.
In the previous studies on human chromosomes, two factors associated with high
mutation rate [4,12] were proposed: (i) the location within 50 Mb from the chromosome
end [12,42] and (ii) A+T content higher than average (59%) [12]. Telomeres by themselves
are considered to be a mechanism to protect chromosomes, since cells do not tolerate the
presence of unprotected chromosome ends [43]. Interestingly, chromosomal DNAs adjacent
to telomeres are vulnerable to DNA damage or mutagenesis [12], partly because of telomere
dysfunction in telomerase null conditions [44]. It is also noted that genes in close proximity
to telomeres are silenced due to the repressive nature of specific telomere-binding proteins
such as heterochromatin [32]. The degree of repression declines with distance from the
telomere, limited to ~100 kb [45]. While a plethora of convincing evidence exists for the first
factor, the high mutation rate associated with A+T rich regions in human chromosomes [12]
has been too complex [10,11] to summarize until the chimpanzee and human genomes
were successfully sequenced [8,9].
We demonstrated the utility of two factors, which were narrowed down from more
than ten factors previously proposed [12]. The strengths of this study lie in the accuracy
of predictability at >80% in CVDs and >90% in a genetic disease of the CNS such as
congenital hydrocephalus [4] by using only two factors: proximity to telomeres and DNA
compositions of the human disease gene. The limitations, likewise, are those human
diseases caused by genetic mutation(s) as well as environmental factors such as sedentary
lifestyle, unhealthy dietary intake, and exposures to toxins playing a complex role, in which
the matching rate between the factors and the disease is only at ~50%.
The clinical utility of the present study is that clinicians can screen causative gene
mutations found in preclinical or animal models in comparison with human chromosome
analysis summarized in this study using a genome data viewer (NIH software) and GC
content calculator (open software). The physical length of several human chromosomes
can also be noted to save time in applying the first factor. A mouse causative gene in mouse
chromosome 1 does not always locate in the same chromosome number of the human
genomes. Therefore, species difference matters in physical length/proximity measure
between a gene and its telomere in humans vs. animals. For example, L1CAM gene, well
known in hydrocephalus research, is in chromosome X of humans and mice. MYC gene,
however, is in human chromosome 8, while in mouse, it is in chromosome 15. The physical
length of chromosome 8 (50 mm) vs. chromosome 15 (35 mm) differs, resulting in a different
potential to meet the first factor. It should also be noted that mouse chromosomes do not
have p- or q-arm.
Our analysis presented in this study suggests that these two factors can explain the
cause of genetic mutations in 79 loci proposed in MH [35] roughly at an 80% rate. In
comparison, these two factors proposed can only explain the cause of idiopathic diseases
such as EH [41] at a 53% rate. The proposed genomic analyses demonstrate an intermediate
matching rate or a mediocre predictability (~75% or less) between the cause of genetic
mutations and the disease in the cases of CHD, aortic aneurysm (TAA), and age-related
degenerative disorders [4], which warrant further investigations on the establishment of
missing links.
4. Materials and Methods
4.1. Database
The literature survey was carried out with emphasis on diseases reported to be
associated with vascular stiffening: congenital heart disease (CHD) [19], thoracic aortic
aneurysm (TAA) [20,21], and hypertension [17,18]. We utilized the PubMed database, as
well as Google Scholar, in order to select the source literature containing candidate genes
or loci with mutations to be analyzed regarding each disease. Combinations of a single
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keyword and the disease name were attempted. If we were unable to locate relevant
literature through the use of a single keyword, a second keyword was added.
4.2. Keywords in Literature Search
The five words ‘gene’, ‘genetic’, ‘mutation’, ‘analysis’, and ‘chromosome’ were used
with the disease name in Google Scholar. For example, the search was done using ‘(a key-
word) and (the disease)’. The search was considered successful if multiple genes or genetic
mutations were clearly tabulated as a causal and/or associated locus in the literature, con-
sistent with the recent report [4]. The second search was conducted with a refined keyword
if no relevant literature was originally located. As a result, genes associated with EH were
found with keywords ‘gene’ and ‘hypertension’ and ‘chromosome’. Genes associated with
MH were found with keywords, ‘genetic mutation’ and ‘hypertension’. Genes associated
with CHD were identified with keywords, ‘genetic analysis’ and ‘congenital heart disease’.
Genes related to TAA were searched for with keywords ‘mutation’ and ‘thoracic aortic
aneurysm’. For each disease, one pertinent piece of literature was selected among the top
5 results sorted by relevance (to the search keyword in Google Scholar) and by recency (the
most recent paper among the top 5). The paper was excluded if the study pertained only to
a single gene. Between two articles from the same group/authors, the more cited article
was selected in the present study (Figure 5).
4.3. Open-Source Software
We utilized the publicly open Genome Data Viewer, version 5.1, (https://www.ncbi.
nlm.nih.gov/genome/gdv/ accessed on 9 May 2021; NIH National Center for Biotechnol-
ogy Information, Bethesda, MD) and GC content calculator (Biologics International Corp,
Indianapolis, IN, USA) to obtain A+T content (https://www.biologicscorp.com/tools/
GCContent/#.XvctCi-z2uV, accessed on 9 May 2021) [4].
Approximation of proximity to a telomere:
The biological basis for the apparently high mutation rate in human chromosomes
has been previously described. We followed the previous method in the approximation
of proximity to a telomere [4]. As a result, in this study, we calculated the nucleotide
compositions of the gene and focused on the position of the gene and its distal end locus of
each arm (telomere) with the following premise:
(1) If recombination frequency [42] is less than (≤) 50 cM, genes are linked;
(2) if recombination frequency is higher than 50 cM, genes are not linked,
where 1 centimorgan (cM) ∼= 1 million base pair (Mb) [46].




Figure 5. A schematic representation of the searching strategy for literature used in the genetic analysis of this study: EH, 
essential hypertension, MH, monogenic hypertension, CHD, congenital hypertension, TAA, thoracic aortic aneurysm. 
4.4. Data Plot and Statistical Methods 
Prism was used to plot a bar graph and box and violin plot of the data obtained dur-
ing analysis with the genome data viewer. Statistical analyses were performed using 
Prism (version 8, GraphPad Software Inc.). Normal distribution of the data was confirmed 
using the Shapiro–Wilk normality test (α < 0.05). A two-sided unpaired t-test was used for 
comparison of two different groups, unless stated differently. Tukey’s multiple compari-
sons test following one-way analysis of variance was used for comparison of more than 
two groups. The difference between data sets was considered significant at p < 0.05; p val-
ues are identified in the figures and legends as * p < 0.05, ** p < 0.01, *** p < 0.005. 
5. Conclusions 
 Two factors reasonably explain the genetic mutations of cardiovascular disorders 
such as MH (>25 rare mutations) and the genetic architecture of hypertension (53 
SNPs) at an 81% matching rate. 
 Our result using the first factor—particularly in MH and the genetic architecture of 
hypertension—contributed by genetic variants suggests that susceptible genes lo-
cated in chromosomes 18 to 22 more likely meet proximity to telomeres (<50 Mb) due 
to their short chromosomal lengths. 
 Factor–nucleotide size relationships suggest that the full-length size of a gene associ-
ated with MH and the genetic architecture of hypertension longer than 6,000 bp likely 
show high A+T content at >59%. 
 If genes susceptible to CVD with mutations do not satisfy two criteria or the factors 
according to the previous suggestion [12], then neutral or deleterious mutations may ap-
pear in a region that is unlikely to be mutated, or the methods by which susceptible genes are 
filtered out (e.g., microsatellite markers vs. next generation sequencing) should be verified, or 
the contribution of environmental factors (e.g., high salt diet, body mass index, and sedentary 
lifestyle) might be more significant than that of genetic factors. 
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causing congenital heart disease (CHD), Table S4: Proximity to telomeres vs. A+T content in genes 
causing congenital heart disease. Table S5: Genes associated with syndromic and non-syndromic 
thoracic aortic aneurysm, Table S6: Mouse CHD genes and associated human diseases. 
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Disease keyword (google scholar) result selected (reason) reason for exclusion
EH: gene and hypertension and chromosome top 1-5 articles rank #5 (recency) top 1-4 (1997-2003)
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4.4. Data Plot and Statistical Methods
Prism was used to plot a bar graph and box and violin plot of the data obtained
during analysis with the genome data viewer. Statistical analyses were performed using
Prism (version 8, GraphPad Software Inc.). Normal distribution of the data was confirmed
using the Shapiro–Wilk normality test (α < 0.05). A two-sided unpaired t-test was used for
comparison of two different groups, unless stated differently. Tukey’s multiple comparisons
test following one-way analysis of variance was used for comparison of more than two
groups. The difference between data sets was considered significant at p < 0.05; p values
are identified in the figures and legends as * p < 0.05, ** p < 0.01, *** p < 0.005.
5. Conclusions
• Two factors reasonably explain the genetic mutations of cardiovascular disorders such
as MH (>25 rare mutations) and the genetic architecture of hypertension (53 SNPs) at
an 81% matching rate.
• Our result using the first factor—particularly in MH and the genetic architecture of
hypertension—contributed by genetic variants suggests that susceptible genes located
in chromosomes 18 to 22 more likely meet proximity to telomeres (<50 Mb) due to
their short chromosomal lengths.
• Factor–nucleotide size relationships suggest that the full-length size of a gene associ-
ated with MH and the genetic architecture of hypertension longer than 6000 bp likely
show high A+T content at >59%.
• If genes susceptible to CVD with mutations do not satisfy two criteria or the factors
according to the previous suggestion [12], then neutral or deleterious mutations may
appear in a region that is unlikely to be mutated, or the methods by which susceptible
genes are filtered out (e.g., microsatellite markers vs. next generation sequencing)
should be verified, or the contribution of environmental factors (e.g., high salt diet,
body mass index, and sedentary lifestyle) might be more significant than that of
genetic factors.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/
10.3390/ijms22105057/s1, Table S1: Proximity to telomeres vs. A+T content in candidate genes of
essential hypertension, Table S2: Survey of factors in genes near the loci associated with hypertension,
Table S3: An outline of genes causing congenital heart disease (CHD), Table S4: Proximity to
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syndromic and non-syndromic thoracic aortic aneurysm, Table S6: Mouse CHD genes and associated
human diseases.
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